tetramethyl Nordihydroguaiaretic Acid – 500 mg

Brand:
Cayman
CAS:
24150-24-1
Storage:
-20
UN-No:
De Minimis - 3077 / 9

tetramethyl Nordihydroguaiaretic acid (TMNDGA) is a synthetic derivative of NDGA, a non-selective lipoxygenase inhibitor. It inhibits Sp1 transcription factor binding at the HIV long terminal repeat promoter and at the α-ICP4 promoter, a gene essential for HSV replication, with IC50 values of 11 and 43.5 µM respectively{16143,16144} TMNDGA induces growth arrest and apoptosis by suppressing Sp1-dependent Cdc2 and survivin gene expression giving rise to its antitumorigenic activity.{16147} The in vivo growth of xenografts in numerous human tumor types was suppressed upon treatment with TMNDGA.{16146} It also inhibits the growth of mouse and human melanomas and human colon cancer in vivo without causing other tissue toxicity.{16145} TMNDGA is currently in Phase I & II clinical trials for treatment of high grade glioma brain tumors.  

 

Available on backorder

SKU: 70302 - 500 mg Category:

Description

A synthetic derivative of NDGA, a non-selective lipoxygenase inhibitor; inhibits Sp1 transcription factor binding at the HIV long terminal repeat promoter and at the α-ICP4 promoter, a gene essential for HSV replication, with IC50 values of 11 and 43.5 µM respectively; has antitumorigenic activity inducing growth arrest and apoptosis


Formal name: 4-[(2R,3S)-4-(3,4-dimethoxyphenyl)-2,3-dimethylbutyl]-1,2-dimethoxy-benzene

Synonyms:  EM-1421|M4N|Tetrameprocol|tetramethyl NDGA|TMNDGA

Molecular weight: 358.5

CAS: 24150-24-1

Purity: ≥95%

Formulation: A crystalline solid